Commentary

Overcoming obesity: Weight-loss drugs are underused

Amjad Kanj, MD, MPH and Diane Levine, MD, FACP
Cleveland Clinic Journal of Medicine October 2020, 87 (10) 602-604; DOI: https://doi.org/10.3949/ccjm.87a.19102
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Pilitsi E,
    2. Farr OM,
    3. Polyzos SA, et al
    . Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism 2019; 92:170–192. doi:10.1016/j.metabol.2018.10.010
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kang JG,
    2. Park CY
    . Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012; 36(1):13–25. doi:10.4093/dmj.2012.36.1.13
    OpenUrlCrossRefPubMed
  3. ↵
    1. Feingold KR,
    2. Anawalt B,
    3. Boyce A et al.
    1. Kumar RB,
    2. Aronne L
    . Pharmacologic treatment of obesity. In: Feingold KR, Anawalt B, Boyce A et al., eds. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000–2020.
  4. ↵
    1. Semla TP,
    2. Ruser C,
    3. Good CB, et al
    . Pharmacotherapy for weight management in the VHA. J Gen Intern Med 2017; 32(suppl 1):70–73. doi:10.1007/s11606-016-3949-y
    OpenUrlCrossRef
  5. ↵
    1. Chan RS,
    2. Woo J
    . Prevention of overweight and obesity: how effective is the current public health approach. Int J Environ Res Public Health 2010; 7(3):765–783. doi:10.3390/ijerph7030765
    OpenUrlCrossRefPubMed
  6. ↵
    1. Puhl RM,
    2. Heuer CA
    . The stigma of obesity: a review and update. Obesity (Silver Spring) 2009; 17(5):941–964. doi:10.1038/oby.2008.636
    OpenUrlCrossRefPubMed
  7. ↵
    1. Onakpoya IJ,
    2. Heneghan CJ,
    3. Aronson JK
    . Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med 2016; 14(1):191. doi:10.1186/s12916-016-0735-y
    OpenUrlCrossRef
  8. ↵
    1. Hendricks EJ
    . Off-label drugs for weight management. Diabetes Metab Syndr Obes 2017; 10:223–234. doi:10.2147/DMSO.S95299
    OpenUrlCrossRef
  9. ↵
    1. Gomez G,
    2. Stanford FC
    . US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond) 2018; 42(3):495–500. doi:10.1038/ijo.2017.287
    OpenUrlCrossRef
  10. ↵
    1. Veerman JL,
    2. Barendregt JJ,
    3. Forster M,
    4. Vos T
    . Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS One 2011; 6(10):e26051. doi:10.1371/journal.pone.0026051
    OpenUrlCrossRefPubMed
  11. ↵
    1. US Congress
    . S.595—Treat and Reduce Obesity Act of 2019. Accessed July 30, 2020. https://www.congress.gov/bill/116th-congress/senate-bill/595/text
  12. ↵
    1. Burguera B,
    2. Schauer P,
    3. Kahan S
    . What to offer the 99% of patients with severe obesity who do not undergo bariatric surgery? Mayo Clin Proc 2019; 94(6):957–960. doi:10.1016/j.mayocp.2018.11.020
    OpenUrlCrossRef

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects